News
MLTX
19.90
-0.45%
-0.09
MoonLake: 'Buy' Sonelokimab BLA Submission HS September And Label Expansion
Seeking Alpha · 16h ago
MoonLake Immunotherapeutics Announces $200 Million Public Offering
TipRanks · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Broadcom, Micron, Qualcomm
Reuters · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Broadcom, Chemours, Qualcomm
Reuters · 2d ago
BUZZ-MoonLake Immunotherapeutics slides after $200 mln share sale
Reuters · 2d ago
FedEx, Cerebras Systems And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
Benzinga · 2d ago
H.C. Wainwright Remains a Buy on MoonLake Immunotherapeutics (MLTX)
TipRanks · 2d ago
MoonLake Immunotherapeutics 9M share Secondary priced at $20.00
TipRanks · 3d ago
MoonLake Immunotherapeutics prices $200M public offering of Class A shares
Seeking Alpha · 3d ago
MoonLake Prices Upsized $200 Million Offering To Advance Sonelokimab Program
NASDAQ · 3d ago
MoonLake Immunotherapeutics prices upsized public offering at USD 200 million
PUBT · 3d ago
MOONLAKE: PRICES OFFERING OF 9 MLN CLASS A SHARES AT $20 PER SHARE
Reuters · 3d ago
MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering
Barchart · 3d ago
MoonLake CFO Matthias Bodenstedt sells 39,120 shares for $862,205.60
PUBT · 3d ago
MoonLake Immunotherapeutics: Label Upside Drives The Next Leg Higher
Seeking Alpha · 3d ago
Guggenheim Remains a Buy on MoonLake Immunotherapeutics (MLTX)
TipRanks · 3d ago
Buy Rating Reaffirmed on Sonelokimab’s Strong HS Data and Regulatory De-Risking; $30 Price Target Maintained
TipRanks · 4d ago
MoonLake Immunotherapeutics Unveils $150 Mln Of Shares And Warrants; Stock Down
NASDAQ · 4d ago
Closing Bell Movers: Avis Budget jumps over 6% on Pentwater settlement
TipRanks · 4d ago
BUZZ-MoonLake Immunotherapeutics falls on planned $150 mln equity raise
Reuters · 4d ago
More
Webull provides a variety of real-time MLTX stock news. You can receive the latest news about MoonLake Immunotherapeutics through multiple platforms. This information may help you make smarter investment decisions.
About MLTX
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.